Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

Rhea-AI Summary

Celcuity (NASDAQ: CELC), a clinical-stage biotechnology company focused on developing targeted oncology therapies, has scheduled its second quarter 2025 financial results release for Thursday, August 14, 2025 after market close.

Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Investors can access the call via phone (domestic: 1-800-717-1738, international: 1-646-307-1865) or through a live webcast. A replay will be available on Celcuity's website after the event.

MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information
To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1726762&tp_key=047c56f7b8. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

View source version of release on GlobeNewswire.com

Contacts: 

Celcuity Inc. 
Brian Sullivan, bsullivan@celcuity.com 
Vicky Hahne, vhahne@celcuity.com 
(763) 392-0123 

ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com 
(415) 513-1284

FAQ

When will Celcuity (CELC) release Q2 2025 earnings?

Celcuity will release its Q2 2025 financial results on Thursday, August 14, 2025 after the market closes.

How can investors access Celcuity's Q2 2025 earnings call?

Investors can join via phone (domestic: 1-800-717-1738, international: 1-646-307-1865) or through the live webcast at 4:30 p.m. Eastern Time.

What is Celcuity's main business focus?

Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for oncology.

Will there be a replay available of Celcuity's Q2 2025 earnings call?

Yes, a replay of the webcast will be available on Celcuity's website following the live event.